This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. Corwin Vance, MD; Bruce J. Bart, MD; Ronald C. Hansen, MD; Richard C. Reichman, MD; Christopher McEwen, MD; Kenneth D. Hatch, MD; Brian Berman, MD, PhD; Daniel J. Tanner, MD

Arch Dermatol. 1986;122(3):272-277.

Abstract
• We conducted a multicenter double-blind study comparing human recombinant intralesional alpha-2 interferon (IFN) and placebo in 237 patients with the clinical diagnosis of condyloma acuminatum or verruca plantaris. A single wart on each patient was injected with 0.1 mL containing 10⁶ IU of IFN, 10⁵ IU of IFN, or placebo three times weekly for three weeks, and the response to treatment was followed up for 12 weeks. Among 91 of the 114 patients with condyloma acuminatum who completed the study, complete clearing of the treated wart occurred in 16 (53%) of 30 patients receiving 10⁶ IU of IFN compared with six (19%) of 32 receiving 10⁵ IU of IFN and four (14%) of 29 receiving placebo. In the group of 100 patients with plantar warts, there was no apparent benefit associated with interferon administration. Seven patients (3%) had treatment discontinued due to adverse reactions. Intralesional alpha-2 IFN is of benefit in the treatment of a single condyloma; its role in the treatment of multiple lesions remains to be clarified. Its role in the treatment of verruca plantaris, where no response was seen, also remains to be clarified.

(Arch Dermatol 1986;122:272-277)

Author Affiliations
From the Department of Dermatology, University of Minnesota Hospitals, Minneapolis (Drs Vance and Bart); the Department of Dermatology, University of Arizona, Tucson (Dr Hansen); the Infectious Disease Unit, University of Rochester (NY) School of Medicine (Dr Reichman); the Department of Dermatology, Tulane University Medical Center, New Orleans (Dr McEwen); the Department of Obstetrics and Gynecology, University of Alabama, Birmingham (Dr Hatch); the Department of Dermatology, Mount Sinai Hospital, New York (Dr Berman); and Schering Corporation, Kenilworth, NJ (Dr Tanner). Dr Berman is now with the University of California-Davis.

Footnotes
Accepted for publication Sept 27, 1985.

A complete listing of the participants in this study appears at the end of this article.

Read before the annual meeting of the Society of Investigational Dermatology, Washington, DC, May 9, 1984.

Reprint requests to the Department of Dermatology, University of Minnesota Hospitals, Box 98 Mayo, Minneapolis, MN 55455 (Dr Vance).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Local treatments for cutaneous warts: systematic review * Commentary: Systematic reviewers face challenges from varied study designs
Gibbs et al.
BMJ 2002;325:461-461.
ABSTRACT | FULL TEXT  

Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts
Beutner et al.
Antimicrob. Agents Chemother. 1998;42:789-794.
ABSTRACT | FULL TEXT  

Carbon Dioxide Laser Vaporization Combined With Perilesionally Injected Interferon Alfa-2b in the Treatment of a Hyperkeratotic Verruca Vulgaris on the Upper Eyelid
Petersen and Nurnberg
Arch Dermatol 1994;130:1369-1370.
ABSTRACT  

Verruca Vulgaris: Treatment With Natural Interferon Alfa Using a Needleless Injector
Naples and Brodell
Arch Dermatol 1993;129:698-700.
ABSTRACT  

Recombinant Interferon Gamma in Condylomata Acuminata
Gross
JAMA 1991;266:2706-2706.
ABSTRACT  

Condylomata Acuminata in the Pediatric Population
Boyd
Arch Pediatr Adolesc Med 1990;144:817-824.
ABSTRACT  

Treatment of Condyloma Acuminatum with Three Different Interferons Administered lntralesionally: A Double-Blind, Placebo-Controlled Trial
REICHMAN et al.
ANN INTERN MED 1988;108:675-679.
ABSTRACT  

Natural Interferon Alfa for Treatment of Condylomata Acuminata
Friedman-Kien et al.
JAMA 1988;259:533-538.
ABSTRACT  

Interferon: Promises, Disappointments, and Tempered Optimism
Edwards
Arch Dermatol 1987;123:743-744.
ABSTRACT  

Intralesional Human Lymphoblastoid Interferon Alpha for the Treatment of Cutaneous, Nongenital Viral Warts
Gibson
Arch Dermatol 1986;122:1098-1099.
ABSTRACT